Gastric Cancer - Pipeline Insight, 2024

Gastric Cancer - Pipeline Insight, 2024

DelveInsight’s, “Gastric Cancer - Pipeline Insight, 2024,”report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gastric Cancer Understanding

Gastric Cancer: Overview

Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. About 95% of the time, stomach cancer starts in the stomach lining and progresses slowly. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer.

Stomach cancer forms when there’s a genetic mutation (change) in the DNA of stomach cells. DNA is the code that tells cells when to grow and when to die. Because of the mutation, the cells grow rapidly and eventually form a tumor instead of dying. The cancer cells overtake healthy cells and may spread to other parts of the body (metastasize).

The most common symptoms of stomach cancer include: difficulty swallowing (dysphagia), weight loss, indigestion (dyspepsia) that doesn't go away, feeling full after eating small amounts, feeling or being sick, and tiredness due to low red blood cells (anaemia). The late complications of gastric cancer includes pathologic peritoneal and pleural effusions, intrahepatic jaundice caused by hepatomegaly etc.

The gastric cancer can be diagnosed by upper endoscopy commonly used to diagnose stomach cancer, endoscopic ultrasound is a special kind of endoscopy that can help stage the cancer, radiologic tests, including a CT scan, barium swallow and MRI, can help identify tumors and other abnormalities that may be cancer-related also by blood tests can offer information about how organs are functioning. Poor organ function may indicate that cancer has spread to that organ.

There are different types of treatment for patients with gastric cancer. Seven types of standard treatment are used: Surgery, Endoscopic mucosal resection, Chemotherapy, Radiation therapy, Chemoradiation, Targeted therapy, and Immunotherapy.

""Gastric Cancer - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Cancer pipeline landscape is provided which includes the disease overview and Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Colorectal Cancer.

Gastric Cancer Emerging Drugs Chapters

This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastric Cancer Emerging Drugs

• Catumaxomab: Linton Pharm Co. Ltd.

Catumaxomab is a bispecific monoclonal antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects. It is co-developed by Trion Pharma and Neovii Biotech. Currently it is in Phase III stage of clinical trial evaluation to treat Gastric Cancer.

• HLX10: Shanghai Henlius Biotech

HLX10, a novel recombinant humanized anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius. The drug candidate works on programmed cell death-1 receptor antagonists and T lymphocyte stimulant mechanism of action. Currently being evaluated in the Phase III studies.

• FLX475: RAPT Therapeutics

FLX475 is an oral, small molecule CCR4 antagonist designed to block the migration of regulatory T cells (Treg) specifically into tumors, but not healthy tissues, without depleting Treg throughout the body. It is in collaboration agreement with Hanmi for specific regions like Korea, Taiwan and China. Currently the drug is being evaluated in Phase II for the treatment of Gastric Cancer.

• Savolitinib: AstraZeneca/HUTCHMED

Savolitinib is an oral, potent and highly selective MET tryokinase inhibitors (TKI). It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. The drug is been developed under global licensing and collaboration agreement with AstraZeneca. The drug is in Phase II stage of clinical trials.

• ASP 2138: Astellas Pharma

ASP-2138 is a bispecific antibody targeting CD3 and claudin 18.2 (CLDN18.2). It is administered through intravenous drip route. The drug candidate is being developed based on XmAb technology. The drug is under clinical development by Xencor and currently drug is in Phase I stage of clinical trials for the treatment of gastric cancer.

• Minnelide : Minneamrita Therapeutics LLC

Minnelide is under clinical development by Minneamrita Therapeutics. It is administered through intravenous and oral routes. The drug candidate is a water soluble analogue of triptolide and is derived from the thunder God vine (Tripterygium wilfordii). It acts by targeting heat shock protein70 (Hsp70). Currently being investigated in a Phase I clinical trial in patients suffering with gastric cancer.

Further product details are provided in the report……..

Colorectal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Gastric Cancer
• There are approx. 180+ key companies which are developing the therapies for Colorectal Cancer. The companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Linton Pharm Co. Ltd.
• Phases

Delve Insight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Colorectal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Gastric Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.

Gastric Cancer Report Insights

• Gastric Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Gastric Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Gastric Cancer drugs?
• How many Gastric Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastric Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastric Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gastric Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Linton Pharm Co. Ltd.
• Shanghai Henlius Biotech
• RAPT Therapeutics
• AstraZeneca
• Astellas Pharma
• Minneamrita Therapeutics
• Aston Science
• Servier Bio-Innovation LLC
• Bukwang Pharmaceutical
• Taiho Oncology, Inc.
• Novartis Pharmaceuticals
• Base Therapeutics (Shanghai) Co., Ltd
• Shanghai Miracogen Inc.
• RemeGen Co., Ltd.
• Idience Co., Ltd.
• BeiGene
• Ono Pharmaceutical Co. Ltd
• Elevar Therapeutics
• R-Pharm
• Innovent Biologics (Suzhou) Co. Ltd.
• MacroGenics
• Sichuan Baili Pharmaceutical Co., Ltd.
• LianBio LLC
• Janssen Pharmaceutical

Key Products

• Catumaxomab
• HLX10
• FLX475
• Savolitinib
• ASP 2138
• Minnelide
• AST 301
• S095029
• Apatinib mesylate
• TAS-102
• AUY922
• NK510
• MRG003
• RC48-ADC
• IDX-1197+XELOX
• Pamiparib
• ONO-4538
• Rivoceranib
• HLX22
• Ixabepilone
• Sintilimab
• Margetuximab
• SI-B003
• Dovitinib
• Infigratinib
• Amivantamab